Skip to main content
Premium Trial:

Request an Annual Quote

Marina Licenses Delivery Technology Rights to ProNai

Premium

Marina Biotech said this week that it has signed an agreement giving DNA oligo drug firm ProNai Therapeutics the exclusive rights to its Smarticle delivery technology for DNA-based drug development.

Under the terms of the deal, Marina could receive up to $14 million for each gene target selected by ProNai, as well as royalties on product sales.

Additional terms were not disclosed.

Marina acquired the Smarticle technology from Novosom for $5 million in stock in 2010 (GSN 7/29/2010).

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.